$CELC
Celcuity Inc

2024 Q1 Form 10-K Financial Statement

#000149315224011549 Filed on March 27, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.846M $1.648M $5.636M
YoY Change 45.49% 59.21% 37.42%
% of Gross Profit
Research & Development $20.65M $18.08M $60.59M
YoY Change 83.07% 70.51% 71.71%
% of Gross Profit
Depreciation & Amortization $29.56K $32.77K $142.8K
YoY Change -32.73% -33.04% -32.31%
% of Gross Profit
Operating Expenses $22.49M $19.73M $66.23M
YoY Change 79.27% 69.51% 68.14%
Operating Profit -$22.49M -$66.23M
YoY Change 79.27% 68.14%
Interest Expense $1.401M $880.8K $5.326M
YoY Change 12.78% 1422.3% 152.9%
% of Operating Profit
Other Income/Expense, Net $881.4K $2.451M
YoY Change 44.7% -350.39%
Pretax Income -$21.61M -$18.85M -$63.78M
YoY Change 81.03% 62.75% 57.99%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$21.61M -$18.85M -$63.78M
YoY Change 81.03% 62.75% 57.99%
Net Earnings / Revenue
Basic Earnings Per Share -$0.64 -$2.69
Diluted Earnings Per Share -$0.64 -$0.65 -$2.69
COMMON SHARES
Basic Shares Outstanding 30.45M shares 24.20M shares 23.68M shares
Diluted Shares Outstanding 33.61M shares 23.68M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $177.7M $180.6M $180.6M
YoY Change 12.82% 7.12% 7.12%
Cash & Equivalents $31.21M $30.66M $30.66M
Short-Term Investments $146.4M $149.9M $149.9M
Other Short-Term Assets $9.861M $10.01M $9.202M
YoY Change 49.79% 56.39% 43.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $187.5M $190.6M $190.6M
YoY Change 14.27% 8.79% 8.79%
LONG-TERM ASSETS
Property, Plant & Equipment $306.0K $228.8K $628.8K
YoY Change 37.02% -12.11% 24.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $657.9K $628.8K $628.8K
YoY Change -15.14% 24.13% 24.13%
TOTAL ASSETS
Total Short-Term Assets $187.5M $190.6M $190.6M
Total Long-Term Assets $657.9K $628.8K $628.8K
Total Assets $188.2M $191.2M $191.2M
YoY Change 14.14% 8.83% 8.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.277M $5.077M $5.077M
YoY Change 105.33% 93.25% 93.24%
Accrued Expenses $11.24M $8.927M $2.647M
YoY Change 269.63% 119.86% 32.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $16.70M $14.19M $14.19M
YoY Change 187.57% 106.19% 106.19%
LONG-TERM LIABILITIES
Long-Term Debt $37.57M $37.04M $37.04M
YoY Change 5.89% 5.87% 5.87%
Other Long-Term Liabilities $182.1K $225.9K $225.9K
YoY Change -49.97% 270.36% 270.36%
Total Long-Term Liabilities $37.75M $37.26M $37.26M
YoY Change 5.32% 6.33% 6.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.70M $14.19M $14.19M
Total Long-Term Liabilities $37.75M $37.26M $37.26M
Total Liabilities $54.44M $51.45M $51.45M
YoY Change 30.72% 22.72% 22.72%
SHAREHOLDERS EQUITY
Retained Earnings -$181.7M -$160.1M
YoY Change 67.86% 66.23%
Common Stock $30.77K $25.51K
YoY Change 40.26% 17.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $133.7M $139.8M $139.8M
YoY Change
Total Liabilities & Shareholders Equity $188.2M $191.2M $191.2M
YoY Change 14.14% 8.83% 8.83%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$21.61M -$18.85M -$63.78M
YoY Change 81.03% 62.75% 57.99%
Depreciation, Depletion And Amortization $29.56K $32.77K $142.8K
YoY Change -32.73% -33.04% -32.31%
Cash From Operating Activities -$17.07M -$18.53M -$53.81M
YoY Change 32.64% 95.5% 49.44%
INVESTING ACTIVITIES
Capital Expenditures $89.68K $37.64K $97.64K
YoY Change 1183.47% -66.41% -38.5%
Acquisitions
YoY Change
Other Investing Activities $3.626M -$41.18M -$4.911M
YoY Change -83.42% -71.38% -96.59%
Cash From Investing Activities $3.536M -$41.22M -$5.008M
YoY Change -83.83% -71.37% -96.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $14.08M 64.66M $64.91M
YoY Change 20627.36% -46.36% -46.05%
NET CHANGE
Cash From Operating Activities -$17.07M -18.53M -$53.81M
Cash From Investing Activities $3.536M -41.22M -$5.008M
Cash From Financing Activities $14.08M 64.66M $64.91M
Net Change In Cash $552.0K 4.911M $6.091M
YoY Change -93.91% -114.92% -110.2%
FREE CASH FLOW
Cash From Operating Activities -$17.07M -$18.53M -$53.81M
Capital Expenditures $89.68K $37.64K $97.64K
Free Cash Flow -$17.16M -$18.57M -$53.91M
YoY Change 33.27% 93.61% 49.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001603454
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
CY2022 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
usd
CY2023 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
usd
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
CY2022 CELC Payments For Secondary Registration Statement Costs
PaymentsForSecondaryRegistrationStatementCosts
usd
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
usd
CY2022 CELC Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
usd
CY2023Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
usd
CY2022Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
usd
CY2022Q4 CELC Miscellaneous Receivable
MiscellaneousReceivable
usd
CY2023Q4 CELC Prepaid On Research And Development
PrepaidOnResearchAndDevelopment
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-38207
CY2023 dei Entity Registrant Name
EntityRegistrantName
Celcuity Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2863566
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
16305 36th
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Avenue North
CY2023 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 100
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Minneapolis
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55446
CY2023 dei City Area Code
CityAreaCode
(763)
CY2023 dei Local Phone Number
LocalPhoneNumber
392-0767
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2023 dei Trading Symbol
TradingSymbol
CELC
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
191274949 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30453120 shares
CY2023 dei Auditor Name
AuditorName
Boulay LLP
CY2023 dei Auditor Location
AuditorLocation
Minneapolis, Minnesota
CY2023 dei Auditor Firm
AuditorFirmId
542
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30662774 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24571557 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
149919974 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
144015954 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
10007849 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
6603026 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
190590597 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
175190537 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
228782 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
260294 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
400019 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
246266 usd
CY2023Q4 us-gaap Assets
Assets
191219398 usd
CY2022Q4 us-gaap Assets
Assets
175697097 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5076699 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2627076 usd
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2449 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
184950 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
191749 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8927094 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4060280 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14188743 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6881554 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
225922 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61002 usd
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
37035411 usd
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
34983074 usd
CY2023Q4 us-gaap Liabilities
Liabilities
51450076 usd
CY2022Q4 us-gaap Liabilities
Liabilities
41925630 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
854134 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
854134 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1120873 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1120873 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
854 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
1121 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25506012 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25506012 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21667250 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21667250 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
25506 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
21667 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
299818965 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
230045566 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160076003 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96296887 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
139769322 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
133771467 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
191219398 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
175697097 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60594005 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35289548 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5636326 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4101543 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
66230331 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
39391091 usd
CY2023 us-gaap Interest Expense
InterestExpense
5326387 usd
CY2022 us-gaap Interest Expense
InterestExpense
2106111 usd
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
7777602 usd
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
1127162 usd
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2451215 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-978949 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63779116 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40370040 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-63779116 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-40370040 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.69
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.69
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.64
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.64
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23679472 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23679472 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15418543 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15418543 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
68710477 usd
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
4638205 usd
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
171710 usd
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
152412 usd
CY2022 CELC Stock Issued During Period Value Issuance Of Common And Preferred Stock Upon Closing Of Private Placement Offering
StockIssuedDuringPeriodValueIssuanceOfCommonAndPreferredStockUponClosingOfPrivatePlacementOffering
100000000 usd
CY2022 CELC Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Issuance With Private Placement Offering
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering
4316534 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5175000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
389763 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-40370040 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
133771467 usd
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
202845 usd
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
388522 usd
CY2023 CELC Exercise Of Common Stock Warrants
ExerciseOfCommonStockWarrants
-22505 usd
CY2023 CELC Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Issuance With Private Placement Offering
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering
7486 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15000251 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
614205 usd
CY2023 CELC Additional Paid In Capital Pre Funded Warrant Issued
AdditionalPaidInCapitalPreFundedWarrantIssued
50000000 usd
CY2023 CELC Issuance Costs Associated With Prefunded Warrants
IssuanceCostsAssociatedWithPrefundedWarrants
-116895 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-63779116 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
139769322 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
139769322 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-63779116 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-40370040 usd
CY2023 us-gaap Depreciation
Depreciation
142772 usd
CY2022 us-gaap Depreciation
Depreciation
210918 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
4901434 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
4638205 usd
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
241752 usd
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
395757 usd
CY2023 us-gaap Paid In Kind Interest
PaidInKindInterest
1810584 usd
CY2022 us-gaap Paid In Kind Interest
PaidInKindInterest
455074 usd
CY2023 CELC Noncash Operating Lease Net
NoncashOperatingLeaseNet
4368 usd
CY2022 CELC Noncash Operating Lease Net
NoncashOperatingLeaseNet
-3243 usd
CY2023 us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
993457 usd
CY2022 us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
142928 usd
CY2023 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
3438018 usd
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
5526381 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2430614 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1077080 usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4866814 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3257387 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53812253 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36008171 usd
CY2023 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
309614521 usd
CY2023 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
314525084 usd
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
143873026 usd
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
97644 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
158768 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5008207 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-144031794 usd
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
22505 usd
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
388522 usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
152412 usd
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
202845 usd
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
171710 usd
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
95721786 usd
CY2022 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
19509037 usd
CY2023 CELC Proceeds From An Atm Offering Net Of Commision And Offering Cost
ProceedsFromAnATMOfferingNetOfCommisionAndOfferingCost
14431186 usd
CY2022 CELC Proceeds From An Atm Offering Net Of Commision And Offering Cost
ProceedsFromAnATMOfferingNetOfCommisionAndOfferingCost
4776046 usd
CY2023 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
49917589 usd
CY2023 CELC Payments For Secondary Registration Statement Costs
PaymentsForSecondaryRegistrationStatementCosts
45805 usd
CY2023 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2716 usd
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2449 usd
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5850 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64911677 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
120325141 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
6091217 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-59714824 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24571557 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84286381 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30662774 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24571557 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
3274051 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1255280 usd
CY2023 CELC Deferred Financing Costs And Offering And Registration Statement Costs Included In Accounts Payable
DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable
56414 usd
CY2022 CELC Deferred Financing Costs And Offering And Registration Statement Costs Included In Accounts Payable
DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable
51020 usd
CY2023 CELC Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
13615 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_840_eus-gaap--UseOfEstimates_znfnLH1JIK65" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zzsN638AO2Ib">Accounting Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management uses estimates and assumptions in preparing these financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be significant. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
30662774 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
24571557 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
149919974 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
144015954 usd
CY2023Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
0 usd
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
33195 usd
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zPxR9dHpCnWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_868_zeCOVw2yHiE2">Risks and Uncertainties</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its initial drug product, gedatolisib, the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval for gedatolisib and its diagnostic tests, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60594005 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35289548 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30662774 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
149919974 usd
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18622423 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20454691 shares
CY2023Q4 CELC Prefunded Warrant Shares
PrefundedWarrantShares
5747787 shares
CY2022Q3 CELC Deemed Dividend
DeemedDividend
272000 usd
CY2022 CELC Increased Net Loss Per Share Basic
IncreasedNetLossPerShareBasic
0.02
CY2022 CELC Increased Net Loss Per Share Diluted
IncreasedNetLossPerShareDiluted
0.02
CY2023Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
149919974 usd
CY2023Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
30995 usd
CY2023Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
149950969 usd
CY2022Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
144015954 usd
CY2022Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
71156 usd
CY2022Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
144087110 usd
CY2023Q4 CELC Prepaid Clinical Trial
PrepaidClinicalTrial
8763150 usd
CY2022Q4 CELC Prepaid Clinical Trial
PrepaidClinicalTrial
5656737 usd
CY2023Q4 CELC Miscellaneous Receivable
MiscellaneousReceivable
805882 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
281364 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
351073 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
157453 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
173416 usd
CY2022Q4 CELC Prepaid On Research And Development
PrepaidOnResearchAndDevelopment
421800 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
10007849 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
6603026 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2090772 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1979512 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1861990 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1719218 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
228782 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
260294 usd
CY2023 us-gaap Depreciation
Depreciation
142772 usd
CY2022 us-gaap Depreciation
Depreciation
210918 usd
CY2023Q4 CELC Accrued Clinical Trial Expense
AccruedClinicalTrialExpense
6464772 usd
CY2022Q4 CELC Accrued Clinical Trial Expense
AccruedClinicalTrialExpense
2246573 usd
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1763316 usd
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
929216 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
641512 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
845524 usd
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
57494 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
38967 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8927094 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4060280 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
400019 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
410872 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
184950 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
225922 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
213537 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
220389 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
74170 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
508096 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
97224 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
410872 usd
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.105 pure
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
212238 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
197767 usd
CY2023 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2411 usd
CY2022 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
5786 usd
CY2023 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
4 usd
CY2022 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
39 usd
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
101957 usd
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
81077 usd
CY2023 us-gaap Lease Cost
LeaseCost
316610 usd
CY2022 us-gaap Lease Cost
LeaseCost
284669 usd
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
308914 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
282086 usd
CY2023 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
4 usd
CY2022 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
39 usd
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2449 usd
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5850 usd
CY2023 CELC Cash Paid For Operating And Finance Leases
CashPaidForOperatingAndFinanceLeases
311367 usd
CY2022 CELC Cash Paid For Operating And Finance Leases
CashPaidForOperatingAndFinanceLeases
287975 usd
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
2100000 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21667250 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1120873 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25506012 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
854134 shares
CY2023 us-gaap Dividends
Dividends
0 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
13011520 usd
CY2022Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2025-09-19
CY2022Q3 CELC Estimated Incremental Fair Value Of Warrants
EstimatedIncrementalFairValueOfWarrants
271988 usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0341 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0486 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0168 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0422 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.771 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.798 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.762 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.796 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q4 CELC Employee Service Sharebased Compensation Nonvested Awards Compensation Cost To Be Recognized Next Twelve Months
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths
4075020 usd
CY2023Q4 CELC Employee Service Share Based Compensation Non Vested Awards Compensation Cost To Be Recognized Within Two Year
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear
2770901 usd
CY2023Q4 CELC Employee Service Sharebased Compensation Nonvested Awards Compensation Cost To Be Recognizedwithin Three Years
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears
1819779 usd
CY2023Q4 CELC Employee Service Share Based Compensation Non Vested Awards Compensation Cost To Be Recognized Within Four Years
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears
906379 usd
CY2023Q4 CELC Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost To Be Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized
9572079 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
4901434 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
4638205 usd
CY2022Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
100000000 usd
CY2022Q3 CELC Prepayment Fee Percentage
PrepaymentFeePercentage
0.030 pure
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
346000 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
35000000 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
35000000 usd
CY2023Q4 CELC Payment In Kind Interest Debt
PaymentInKindInterestDebt
2565660 usd
CY2022Q4 CELC Payment In Kind Interest Debt
PaymentInKindInterestDebt
755075 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
480810 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
707001 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
49439 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
65000 usd
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
37035411 usd
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
34983074 usd
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
14087122 usd
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
18782830 usd
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
4695708 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
37565660 usd
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-13394000 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8478000 usd
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-82000 usd
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-64000 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13542000 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9543000 usd
CY2023 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
550000 usd
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1347000 usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
484000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
207000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
103000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2141000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1419000 usd
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
393000 usd
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
364000 usd
CY2023Q4 CELC Deferred Tax Assets Rightofuse Assets
DeferredTaxAssetsRightofuseAssets
-85000 usd
CY2022Q4 CELC Deferred Tax Assets Rightofuse Assets
DeferredTaxAssetsRightofuseAssets
-52000 usd
CY2023Q4 CELC Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
-87000 usd
CY2022Q4 CELC Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
-53000 usd
CY2023Q4 CELC Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Irc174 Expenditures
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures
13900000 usd
CY2022Q4 CELC Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Irc174 Expenditures
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures
3326000 usd
CY2023Q4 CELC Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Startup Expenditures
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures
11029000 usd
CY2022Q4 CELC Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Startup Expenditures
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures
10333000 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8461000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7045000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
36133000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22591000 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
25900000 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
700000 usd
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-24-011549-index-headers.html Edgar Link pending
0001493152-24-011549-index.html Edgar Link pending
0001493152-24-011549.txt Edgar Link pending
0001493152-24-011549-xbrl.zip Edgar Link pending
celc-20231231.xsd Edgar Link pending
ex23-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
ex4-2.htm Edgar Link pending
ex97.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
form10-k_001.jpg Edgar Link pending
form10-k_003.jpg Edgar Link pending
form10-k_005.jpg Edgar Link pending
form10-k_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
celc-20231231_lab.xml Edgar Link unprocessable
celc-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
celc-20231231_def.xml Edgar Link unprocessable
celc-20231231_cal.xml Edgar Link unprocessable